

FDA COVER PAGE

TITLE OF RESOURCE:

Illuminate Hypersomnia: Voice of the Patient Report from the Externally-Led Patient-Focused Drug Development Meeting on Idiopathic Hypersomnia (IH)



AUTHORS, REVIEWERS & COLLABORATORS:

Primary Author: K. Kimberly McCleary, Kith Collective

Reviewers: Lindsay Jesteadt, PhD, Sleep Consortium; Samantha Mayberry, Kith Collective; Lynn Marie Trotti, MD, Emory University; and Claire Wylds-Wright, MFA, Sleep Consortium

Design and Layout: Julie Rathjens of Hello Brand

Meeting Moderation: Kim McCleary and Lindsay Jesteadt, PhD

Video Production: Dudley Digital Works

DISCLOSURES:

The host organization, Sleep Consortium, receives funding from pharmaceutical companies in the form of sponsorship of programs and events, including the Illuminate Hypersomnia EL-PFDD Initiative. None of the companies supporting Sleep Consortium were involved in planning or developing the content of the meeting, the survey, this report, or related communications.

The Kith Collective, LLC, is a professional services firm that provides consulting and patient engagement services to patient advocacy organizations and life science companies. Sleep Consortium engaged principals Kim McCleary and Samantha Mayberry to guide and document the Illuminate Hypersomnia EL-PFDD meeting, survey, and related communications. This engagement presented no conflicts of interest with other clients of record.

FUNDING RECEIVED OR GRANTED:

Alkermes, Avadel, Centessa, Harmony Biosciences, Jazz Pharmaceuticals, Takeda, and Zevra Therapeutics provided unrestricted educational grants in support of the Illuminate Hypersomnia Initiative. Sleep Consortium retained sole authority to develop the initiative, the meeting content, and the survey and to select speakers and panelists. Sleep Consortium maintained full editorial control of all written materials, including this report.

VERSION DATE:

September 16, 2024; available at <https://sleepconsortium.org/illuminate-hypersomnia/>
This document has not been revised and/or modified in any way after the report date.

PERMISSION:

Sleep Consortium has received all necessary permissions to submit this resource to the FDA and link to it from the FDA website. Doing so will not violate the proprietary rights of any other entity.

POINT OF CONTACT:

Lindsay Jesteadt, PhD, Co-Founder and CEO, Sleep Consortium (lindsayj@sleepconsortium.org)